MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS

WIPO Patent Application WO2002100813

A3

Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, -CH2-or-CH2CH2-; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R1 and W. R1 is (CH2)n-CH(OR2)-(CH2)mE, -(CH)=C(OR2)-(CH2)mE, -(CH2)n-CH(Y)-(CH2)mE or (CH)=C(Y)-(CH2)mE; wherein E is COOR3, C1-C3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C1-C6 alkyl, haloalkyl and aryl-C0-4-alkyl; R2 is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, -COR4, -COOR4, -CONR5R6, -C(S)R4, -C(S)OR4 or C(S)NR5R6. R3 is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O-, CH2-, -CH2CH2- or CH=CH- and is bonded to a carbon atom in Phenyl Ring A that is ortho to R1. R4-R6 are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

BROOKS DAWN ALISA (US)
WARSHAWSKY ALAN M (US)
MONTROSE-RAFEZADEH CHAHRZAD (US)
REIFEL-MILLER ANNE (US)
PRIETO LOURDES (ES)
ROJO ISABEL (ES)
MARTIN JOSE ALFREDO (ES)
GONZALES GARCIA MARIA ROSARIO (ES)
TORRADO ALICIA (ES)
FERRITTO CRESPO RAFAEL (ES)
LAMAS-PETEIRA CARLOS (ES)
MARTIN-ORTEGA FINGER MARIA (ES)
ARDECKY ROBERT J (US)

PCT/US2002/016950

November 27, 2003

May 30, 2002

Click for automatic bibliography generation  

LILLY CO ELI (US)
LIGAND PHARM INC (US)
BROOKS DAWN ALISA (US)
WARSHAWSKY ALAN M (US)
MONTROSE-RAFEZADEH CHAHRZAD (US)
REIFEL-MILLER ANNE (US)
PRIETO LOURDES (ES)
ROJO ISABEL (ES)
MARTIN JOSE ALFREDO (ES)
GONZALES GARCIA MARIA ROSARIO (ES)
TORRADO ALICIA (ES)
FERRITTO CRESPO RAFAEL (ES)
LAMAS-PETEIRA CARLOS (ES)
MARTIN-ORTEGA FINGER MARIA (ES)
ARDECKY ROBERT J (US)

A61K31/19; A61K31/275; A61K31/343; A61K31/352; A61K31/353; A61K31/36; A61K31/381; A61K31/40; A61K31/4035; A61K31/404; A61K31/41; A61K31/4164; A61K31/428; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4453; C07D295/08; A61K31/47; A61K31/472; A61K31/495; A61K31/5375; A61K45/00; A61P1/14; A61P3/00; A61P3/04; A61P3/06; A61P3/10; A61P9/00; A61P9/04; A61P9/12; A61P15/00; C07B61/00; C07C51/09; C07C59/68; C07C59/72; C07C59/90; C07C213/08; C07C217/20; C07C217/84; C07C217/92; C07C219/10; C07C233/25; C07C233/29; C07C233/60; C07C233/75; C07C235/56; C07C235/64; C07C239/12; C07C251/48; C07C255/54; C07D209/08; C07D209/48; C07D213/30; C07D213/64; C07D213/82; C07D215/12; C07D215/14; C07D217/02; C07D233/60; C07D257/04; C07D277/64; C07D295/096; C07D295/10; C07D295/112; C07D295/185; C07D307/79; C07D307/83; C07D307/91; C07D307/93; C07D311/30; C07D311/32; C07D317/20; C07D317/22; C07D317/54; C07D317/64; C07D333/16; C07D333/76; C07D335/02; C07D521/00; C07F7/18; (IPC1-7): C07C59/68; C07C59/90; C07C59/72; C07C239/12; C07D311/30; C07D307/91; C07C219/10; C07D213/30; C07D215/14; C07D295/08; C07C217/94; A61K31/192; A61K31/195; A61P9/00; A61P3/04; A61P3/06; A61P3/00

WO2002100812A1	2002-12-19
WO2002080899A1	2002-10-17
WO2001079150A1	2001-10-25
WO2001025181A1	2001-04-12
WO2001016120A1	2001-03-08
WO2002016332A1	2002-02-28
WO1997031907A1	1997-09-04

HAIGH, D. ET AL: "Non-thiazolidinedione Antihyperglycaemic Agents. Part 3: The Effects of Stereochemistry on the Potency of alpha-Methoxy-beta-phenylpropanoic Acids.", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 7, - 1999, pages 821 - 830, XP002231306

View/Download PDF      PDF Help

Previous Patent: INBITION OF THE DEHYDROCHLORINATION REACTION OF POLYCHLORINATED ALKANES

Next Patent: PROCESS FOR PRODUCING 2−ALKYL−2−ADAMANTYL &lpar METH&rpar ACRYLATE